Vous avez cherché: osimertinib (Anglais - Croate)

tagrisso 40 mg tablets osimertinib
tagrisso 40 mg tablete osimertinib

it contains the active substance osimertinib.
sadrži djelatnu tvar osimertinib.

effects of osimertinib on p-gp and bcrp
učinci osimertiniba na p-gp i bcrp

tagrisso 40 mg film-coated tablets osimertinib
tagrisso 40 mg filmom obložene tablete osimertinib

carcinogenicity studies have not been performed with osimertinib.
ispitivanja kancerogenosti nisu provedena s osimertinibom.

osimertinib is a tyrosine kinase inhibitor (tki).
osimertinib je inhibitor tirozin kinaze.

active substances that may decrease osimertinib plasma concentrations
djelatne tvari koje mogu smanjiti koncentracije osimertiniba u plazmi

effect of gastric acid reducing active substances on osimertinib
učinak djelatnih tvari koje smanjuju želučanu kiselinu na osimertinib

strong cyp3a4 inducers can decrease the exposure of osimertinib.
jaki induktori cyp3a4 mogu smanjiti izloženost osimertinibu.

each 40 mg film-coated tablet contains 40 mg of osimertinib.
svaka filmom obložena tableta od 40 mg sadrži 40 mg osimertiniba.

osimertinib did not cause genetic damage in in vitro and in vivo assays.
osimertinib nije uzrokovao genetička oštećenja u in vitro i in vivo analizama.

it is not known whether osimertinib or its metabolites are excreted in human milk.
nije poznato izlučuje li se osimertinib ili njegovi metaboliti u majčino mlijeko u ljudi.

based on in vitro studies, osimertinib is a competitive inhibitor of bcrp transporters.
temeljeno na in vitro ispitivanjima, osimertinib je kompetitivni inhibitor bcrp transportera.

based on studies in animals, female fertility may be impaired by treatment with osimertinib.
na temelju ispitivanja u životinja, plodnost u ženki može biti smanjena kod terapije osimertinibom.

tagrisso 40 mg film-coated tablets tagrisso 80 mg film-coated tablets osimertinib
tagrisso 40 mg filmom obložene tablete tagrisso 80 mg filmom obložene tablete osimertinib

in vitro studies have demonstrated that the phase i metabolism of osimertinib is predominantly via cyp3a4 and cyp3a5.
in vitro ispitivanja su pokazala da se i. faza metabolizma osimertiniba pretežno odvija preko cyp3a4 i cyp3a5.

tagrisso contains the active substance osimertinib which belongs to the protein kinase inhibitor class of anticancer medicines.
tagrisso sadrži djelatnu tvar osimertinib, koja pripada skupini lijekova protiv raka pod nazivom inhibitori protein kinaze.

based on in vitro studies, osimertinib is not an inhibitor of ugt1a1 and ugt2b7 at clinically relevant concentrations hepatically.
na temelju in vitro ispitivanja, pri klinički relevantnim koncentracijama u jetri, osimertinib nije inhibitor ugt1a1 i ugt2b7.

based on a pharmacokinetic analysis of 44 patients with mild hepatic impairment and 330 patients with normal hepatic function osimertinib exposures were similar.
na temelju farmakokinetičkih analiza u 44 bolesnika s blagim oštećenjem funkcije jetre i 330 bolesnika s normalnom funkcijom jetre, izloženosti osimertinibu bile su slične.

administration of osimertinib once daily results in approximately 3 fold accumulation with steady-state exposures achieved by 15 days of dosing.
primjena osimertiniba jedanput dnevno rezultirala je približno trostrukom akumulacijom uz postizanje izloženosti u stanju dinamičke ravnoteže nakon 15 dana doziranja.